Michael Parrella
Medical · Knightdale, NCNPI 1689145476
Payments from drug & device makers
Across 95 payments — averaging $15.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$218
- AbbVie$216
- Johnson & Johnson$166
- GSK$136
- Amarin Pharma, Inc.$118
- E.r. Squibb & Sons, L.L.C.$93
- plus $554 from 15 others
What the payments were for
- Food & beverage$1,501100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 15 | $218 |
| AbbVie | 16 | $216 |
| Johnson & Johnson | 9 | $166 |
| GSK | 11 | $136 |
| Amarin Pharma, Inc. | 7 | $118 |
| E.r. Squibb & Sons, L.L.C. | 5 | $93 |
| Lilly USA, LLC | 4 | $70 |
| AstraZeneca | 4 | $65 |
| Nestle Healthcare Nutrition Inc. | 4 | $60 |
| Pfizer | 3 | $57 |
| Biohaven Pharmaceuticals, Inc. | 3 | $53 |
| Novartis | 3 | $50 |
| Merck | 3 | $42 |
| Axsome Therapeutics, Inc. | 1 | $29 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Insulet Corporation | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Boehringer Ingelheim | 1 | $18 |
| Amgen | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Supernus Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$1,501 in reported general payments places this provider in the 70th percentile of 878 medical providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 63 | $72,515 |
| EliquisApixaban | 71 | $68,884 |
| FarxigaDapagliflozin Propanediol | 49 | $66,929 |
| OzempicSemaglutide | 25 | $41,752 |
| XareltoRivaroxaban | 36 | $22,672 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 17 | $18,446 |
| MyrbetriqMirabegron | 13 | $17,092 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $8,331 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 17 | $8,018 |
| Atorvastatin Calcium | 327 | $2,563 |
| Novolog FlexpenInsulin Aspart | 16 | $2,267 |
| Rosuvastatin Calcium | 167 | $1,704 |
| Levetiracetam | 20 | $1,645 |
| Amlodipine Besylate | 294 | $1,448 |
| Levothyroxine Sodium | 101 | $1,234 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Stiolto Respimat | $18 | $80,84675 claims |
| PfizerEliquis | $57 | $68,88471 claims |
| AstraZenecaFarxiga | $65 | $66,92949 claims |
| Novo NordiskOzempic | $218 | $41,75225 claims |
| Johnson & JohnsonXarelto | $166 | $22,67236 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $14 | $18,44617 claims |
| GSKAnoro Ellipta | $136 | $8,01817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 878 medical providers in North Carolina.
Other medical in Knightdale
- Grace McLaurinHickory$553K
- Joel ThompsonCharlotte$269K
- Virginia JethroCary$213K
- Payal Soni-PatelAsheville$76K
- William JarrettElkin$59K
- Amanda ZimmermanWinston Salem$48K
- David TaylorMorehead City$40K
- Katherine CardSalisbury$39K
- John RobbinsWinston Salem$26K
- Ashley TipperStatesville$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.